BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 37 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,400 | -90.3% | 11,994 | 0.0% | 0.00% | – |
| Q2 2023 | $24,707 | -37.6% | 11,994 | 0.0% | 0.00% | – |
| Q1 2023 | $39,579 | +101.2% | 11,994 | 0.0% | 0.00% | – |
| Q4 2022 | $19,670 | -61.4% | 11,994 | +4.0% | 0.00% | – |
| Q3 2022 | $51,000 | +59.4% | 11,528 | 0.0% | 0.00% | – |
| Q2 2022 | $32,000 | -22.0% | 11,528 | -5.9% | 0.00% | – |
| Q1 2022 | $41,000 | -16.3% | 12,250 | 0.0% | 0.00% | – |
| Q4 2021 | $49,000 | -5.8% | 12,250 | -23.0% | 0.00% | – |
| Q3 2021 | $52,000 | -14.8% | 15,899 | 0.0% | 0.00% | – |
| Q2 2021 | $61,000 | -82.0% | 15,899 | -82.1% | 0.00% | – |
| Q1 2021 | $339,000 | -16.1% | 88,583 | -0.9% | 0.00% | – |
| Q4 2020 | $404,000 | -73.5% | 89,359 | -0.9% | 0.00% | – |
| Q3 2020 | $1,526,000 | +86.1% | 90,161 | +23.2% | 0.00% | – |
| Q2 2020 | $820,000 | +1201.6% | 73,182 | +442.9% | 0.00% | – |
| Q1 2020 | $63,000 | +16.7% | 13,479 | +6.1% | 0.00% | – |
| Q4 2019 | $54,000 | -3.6% | 12,705 | -12.1% | 0.00% | – |
| Q3 2019 | $56,000 | -1.8% | 14,462 | 0.0% | 0.00% | – |
| Q2 2019 | $57,000 | -9.5% | 14,462 | 0.0% | 0.00% | – |
| Q1 2019 | $63,000 | +18.9% | 14,462 | -2.8% | 0.00% | – |
| Q4 2018 | $53,000 | -7.0% | 14,872 | 0.0% | 0.00% | – |
| Q3 2018 | $57,000 | -1.7% | 14,872 | -0.0% | 0.00% | – |
| Q2 2018 | $58,000 | -1.7% | 14,873 | -20.6% | 0.00% | – |
| Q1 2018 | $59,000 | +1.7% | 18,727 | +25.9% | 0.00% | – |
| Q4 2017 | $58,000 | -4.9% | 14,873 | 0.0% | 0.00% | – |
| Q3 2017 | $61,000 | -1.6% | 14,873 | 0.0% | 0.00% | – |
| Q2 2017 | $62,000 | -1.6% | 14,873 | 0.0% | 0.00% | – |
| Q1 2017 | $63,000 | +61.5% | 14,873 | -3.2% | 0.00% | – |
| Q4 2016 | $39,000 | +2.6% | 15,366 | -2.4% | 0.00% | – |
| Q3 2016 | $38,000 | -13.6% | 15,741 | -13.6% | 0.00% | – |
| Q2 2016 | $44,000 | -10.2% | 18,228 | -0.9% | 0.00% | – |
| Q1 2016 | $49,000 | -5.8% | 18,401 | +0.9% | 0.00% | – |
| Q4 2015 | $52,000 | +23.8% | 18,228 | 0.0% | 0.00% | – |
| Q3 2015 | $42,000 | -36.4% | 18,228 | 0.0% | 0.00% | – |
| Q2 2015 | $66,000 | -15.4% | 18,228 | +4.2% | 0.00% | – |
| Q1 2015 | $78,000 | – | 17,498 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 242,850 | $923,000 | 0.13% |
| ABNER HERRMAN & BROCK LLC | 241,500 | $918,000 | 0.13% |
| Weaver Consulting Group | 48,881 | $186,000 | 0.10% |
| Tibra Equities Europe Ltd | 87,000 | $331,000 | 0.10% |
| Ikarian Capital, LLC | 293,200 | $1,115,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 60,238 | $229,000 | 0.03% |
| Ergoteles LLC | 124,329 | $472,000 | 0.01% |
| CFO4Life Group, LLC | 12,003 | $46,000 | 0.01% |
| HighPoint Advisor Group LLC | 17,033 | $65,000 | 0.01% |
| BOOTHBAY FUND MANAGEMENT, LLC | 32,836 | $125,000 | 0.00% |